Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Sodium shale oil sulfonate is effective against dandruff, acne -- HBA Global Expo.

This article was originally published in The Rose Sheet

  • News
  • The Rose Sheet

Executive Summary

SODIUM SHALE OIL SULFONATE OTC NDA for the treatment of dandruff and blemishes has been submitted to FDA, Gudrun Mays, PhD, Ichthyol-Gesellschaft, Cordes, Hermanni & Co., said at a June 9 HBA Global Expo seminar in New York City. The Hamburg, Germany-based company is working on gaining FDA approval of its new drug application with Upper Saddle River, N.J.-based International Sourcing. SSOS is marketed for acne and dandruff indications in Germany and France.

Table

View full table

Tags:
Latest Headlines

Epitel Gets 510(k) Clearance On Remote EEG Technology

Valuable Health Data Sources For Medtech Industry Come A Step Closer In The EU

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

Discreet Gait Freezing Solution Brings Therapy With The Tap Of An Apple Watch

See All
UsernamePublicRestriction

Register

RS004284

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By